Table 2.
The Risk of Acquisition of Cervical and Anal HPV Infection After a Coinfection With Other HPV Types at the Same Anatomic Site
| Incident HPV Infectiona | Prior HPV Coinfectionb | Anal HPV |
Cervical HPV |
||||
| Eventsc | Follow-upd | Hazard Ratioe (95% CI) | Eventsc | Follow-upd | Hazard Ratioe (95% CI) | ||
| Any HPV | None | 208 | 944.2 | 231 | 1071.2 | ||
| Any HPV | 91 | 421.5 | 1.29 (1.00–1.65) | 168 | 785.0 | 1.66 (1.35–2.04) | |
| Any HPV | None | 247 | 1125.0 | 268 | 1225.6 | ||
| HR-HPV | 52 | 240.8 | 1.33 (0.98–1.81) | 131 | 630.5 | 1.82 (1.47–2.24) | |
| Any HPV | None | 230 | 1054.4 | 252 | 1170.0 | ||
| LR-HPVf | 69 | 311.4 | 1.23 (0.93–1.63) | 147 | 686.2 | 2.39 (1.93–2.96) | |
| HR-HPV | None | 81 | 369.7 | 96 | 433.8 | ||
| Any HPV | 40 | 187.4 | 1.28 (0.87–1.90) | 58 | 261.5 | 1.48 (1.05–2.08) | |
| HR-HPV | None | 103 | 477.3 | 108 | 479.7 | ||
| HR-HPV | 18 | 79.8 | 1.00 (0.60–1.67) | 46 | 215.7 | 1.75 (1.23–2.48) | |
| HR-HPV | None | 88 | 399.9 | 102 | 464.9 | ||
| LR-HPVf | 33 | 157.2 | 1.27 (0.83–1.95) | 52 | 230.5 | 2.20 (1.55–3.12) | |
| LR-HPVf | None | 127 | 574.5 | 135 | 637.3 | ||
| Any HPV | 51 | 234.1 | 1.31 (0.95–1.80) | 110 | 523.5 | 1.78 (1.38–2.31) | |
| LR-HPVf | None | 144 | 647.6 | 160 | 746.0 | ||
| HR-HPV | 34 | 161.0 | 1.60 (1.09–2.34) | 85 | 414.8 | 1.85 (1.42–2.42) | |
| LR-HPVf | None | 142 | 654.5 | 150 | 705.1 | ||
| LR-HPVf | 36 | 154.1 | 1.24 (0.86–1.80) | 95 | 455.7 | 2.51 (1.91–3.29) | |
NOTE. High-risk (oncogenic) types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; possibly oncogenic types 26, 34, 53, 66, 69, 70, 73, and 82; non-oncogenic types 6, 11, 40, 42, 44, 54, 61, 72, 81, and 89; undetermined-risk types 62, 67, 71, 83, and 84.
CI, confidence interval; HPV, human papillomavirus; HR-HPV, high-risk HPV; LR-HPV, low-risk HPV.
Incident (detected at a visit other than the first) HPV infection at the indicated anatomic site.
Infection with the other HPV genotypes at the clinic visit preceding the index HPV type acquisition.
The number of incident HPV infections at the indicated anatomic site during the study period.
Cumulative follow-up (months) across all participants/visits for the indicated exposure group.
Reference: no prior HPV coinfection at the indicated anatomic site. Adjusted for age of participants at study entry and prior concordant HPV infection at the other anatomic site.
Includes possibly oncogenic, non-oncogenic, and undetermined-risk HPV types.